BioCentury | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

...of medicine at Stanford University and was previously CMO, EVP and head of R&D of Galena Biopharma Inc....
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...Ltd. (Suzhou, China) hired Thomas Knapp as SVP, general counsel. He was general counsel of Galena Biopharma Inc....
BioCentury | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

...by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals...
...and fluorescein angiography, and best corrected visual acuity (BCVA) Status: Phase I/II data Milestone: NA Sandi Wong RXI-109 RXi Pharmaceuticals...
BioCentury | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

...terms. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass. Iovance Biotherapeutics (NASDAQ:IOVA), San Carlos, Calif. Business: Cancer Shannon Lehnbeuter Iovance Biotherapeutics RXi Pharmaceuticals...
BioCentury | Apr 6, 2018
Clinical News

Sellas reports Phase IIb TNBC data for NeuVax combo

...compared with the control arm (HR=0.67). Sellas gained NeuVax through its August 2017 merger with Galena Biopharma Inc....
...Disease-free survival (DFS); safety Status: Phase IIb data Milestone: NA Elizabeth S. Eaton Herceptin, trastuzumab (RG597) NeuVax, nelipepimut-s (E75) Galena Biopharma Inc. Sellas...
BioCentury | Apr 2, 2018
Clinical News

Sellas rises on Phase IIb TNBC data

...compared with the control arm (HR=0.67). Sellas gained NeuVax through its August 2017 merger with Galena Biopharma Inc....
...The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Herceptin. Elizabeth S. Eaton Herceptin, trastuzumab (RG597) NeuVax, nelipepimut-s (E75) Galena Biopharma Inc. Sellas...
BioCentury | Dec 1, 2017
Company News

Sellas, Merck to collaborate on Phase I/II trial in cancer

...galinpepimut-S from Memorial Sloan Kettering Cancer Center. In August, Sellas announced plans to merge with Galena Biopharma Inc.(NASDAQ:GALE...
BioCentury | Oct 13, 2017
Emerging Company Profile

CBT’s silk road

...Gavin Choy was SVP of clinical sciences and operations at California-based oncology and hematology play Galena Biopharma Inc....
...York, N.Y. CBT Pharmaceuticals Inc., Santa Clara, Calif. Crown Bioscience International Inc. (TPEx:6554), Taipei, Taiwan Galena Biopharma Inc....
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Canbridge's U.S. office in Cambridge, Mass. He was CFO of Pfenex Inc. (NYSE-M:PFNX). RNAi company RXi Pharmaceuticals...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...business and strategy officer of Sellas Life Sciences Group (Hamilton, Bermuda), which is merging with Galena Biopharma Inc....
Items per page:
1 - 10 of 194
BioCentury | May 15, 2019
Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

...of medicine at Stanford University and was previously CMO, EVP and head of R&D of Galena Biopharma Inc....
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...Ltd. (Suzhou, China) hired Thomas Knapp as SVP, general counsel. He was general counsel of Galena Biopharma Inc....
BioCentury | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

...by 6.9%. RXI-109 is a self-delivering rxRNA (sd-rxRNA) compound targeting connective tissue growth factor (CTGF). RXi Pharmaceuticals...
...and fluorescein angiography, and best corrected visual acuity (BCVA) Status: Phase I/II data Milestone: NA Sandi Wong RXI-109 RXi Pharmaceuticals...
BioCentury | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

...terms. RXi Pharmaceuticals Corp. (NASDAQ:RXII), Marlborough, Mass. Iovance Biotherapeutics (NASDAQ:IOVA), San Carlos, Calif. Business: Cancer Shannon Lehnbeuter Iovance Biotherapeutics RXi Pharmaceuticals...
BioCentury | Apr 6, 2018
Clinical News

Sellas reports Phase IIb TNBC data for NeuVax combo

...compared with the control arm (HR=0.67). Sellas gained NeuVax through its August 2017 merger with Galena Biopharma Inc....
...Disease-free survival (DFS); safety Status: Phase IIb data Milestone: NA Elizabeth S. Eaton Herceptin, trastuzumab (RG597) NeuVax, nelipepimut-s (E75) Galena Biopharma Inc. Sellas...
BioCentury | Apr 2, 2018
Clinical News

Sellas rises on Phase IIb TNBC data

...compared with the control arm (HR=0.67). Sellas gained NeuVax through its August 2017 merger with Galena Biopharma Inc....
...The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Herceptin. Elizabeth S. Eaton Herceptin, trastuzumab (RG597) NeuVax, nelipepimut-s (E75) Galena Biopharma Inc. Sellas...
BioCentury | Dec 1, 2017
Company News

Sellas, Merck to collaborate on Phase I/II trial in cancer

...galinpepimut-S from Memorial Sloan Kettering Cancer Center. In August, Sellas announced plans to merge with Galena Biopharma Inc.(NASDAQ:GALE...
BioCentury | Oct 13, 2017
Emerging Company Profile

CBT’s silk road

...Gavin Choy was SVP of clinical sciences and operations at California-based oncology and hematology play Galena Biopharma Inc....
...York, N.Y. CBT Pharmaceuticals Inc., Santa Clara, Calif. Crown Bioscience International Inc. (TPEx:6554), Taipei, Taiwan Galena Biopharma Inc....
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Canbridge's U.S. office in Cambridge, Mass. He was CFO of Pfenex Inc. (NYSE-M:PFNX). RNAi company RXi Pharmaceuticals...
BioCentury | Aug 11, 2017
Company News

Management tracks: Orchard, Maverick, Pieris

...business and strategy officer of Sellas Life Sciences Group (Hamilton, Bermuda), which is merging with Galena Biopharma Inc....
Items per page:
1 - 10 of 194